Probiotic supplementation and systemic inflammation in relapsing-remitting multiple sclerosis: A randomized, double-blind, placebo-controlled trial (vol 16, 901846, 2022)

被引：1
|
作者：
Rahimlou, Mehran [1 ,2 ]
Nematollahi, Shima [1 ]
Husain, Durdana [1 ]
Banaei-Jahromi, Nasrin [3 ]
Majdinasab, Nastaran [4 ]
Hosseini, Seyed Ahmad [1 ]
机构：
[1] Ahvaz Jundishapur Univ Med Sci, Clin Sci Res Inst, Nutr & Metab Dis Res Ctr, Ahvaz, Iran
[2] Zanjan Univ Med Sci, Fac Med, Dept Nutr, Zanjan, Iran
[3] Ahvaz Jundishapur Univ Med Sci, Sch Allied Med Sci, Dept Nutr, Ahvaz, Iran
[4] Ahvaz Jundishapur Univ Med Sci, Sch Med, Dept Neurol, Ahvaz, Iran
来源：
FRONTIERS IN NEUROSCIENCE | 2022年 / 16卷
关键词：
probiotic; multiple sclerosis; inflammation; clinical trial; gut microbiome;
D O I：
10.3389/fnins.2022.1085572
中图分类号：
Q189 [神经科学];
学科分类号：
071006 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Randomized, double-blind, placebo-controlled study of subcutaneous interferon beta-1a in relapsing-remitting multiple sclerosis: a categorical disability trend analysis
    Liu, C
    Blumhardt, LD
    MULTIPLE SCLEROSIS JOURNAL, 2002, 8 (01) : 10 - 14
  • [42] Immunomodulatory effects of probiotic supplementation in patients with asthma: a randomized, double-blind, placebo-controlled trial
    Sina Sadrifar
    Tannaz Abbasi-Dokht
    Sarvenaz Forouzandeh
    Farhad Malek
    Bahman Yousefi
    Amir Salek Farrokhi
    Jafar Karami
    Rasoul Baharlou
    Allergy, Asthma & Clinical Immunology, 19
  • [43] Immunomodulatory effects of probiotic supplementation in patients with asthma: a randomized, double-blind, placebo-controlled trial
    Sadrifar, Sina
    Abbasi-Dokht, Tannaz
    Forouzandeh, Sarvenaz
    Malek, Farhad
    Yousefi, Bahman
    Farrokhi, Amir Salek
    Karami, Jafar
    Baharlou, Rasoul
    ALLERGY ASTHMA AND CLINICAL IMMUNOLOGY, 2023, 19 (01):
  • [44] Placebo-controlled trials in relapsing-remitting multiple sclerosis: are they still needed?
    Waschbisch, Anne
    Derfuss, Tobias
    FUTURE NEUROLOGY, 2012, 7 (01) : 37 - 44
  • [45] A randomized, double-blind, placebo-controlled study of oral hydrolytic enzymes in relapsing multiple sclerosis
    Baumhackl, U
    Kappos, L
    Radue, EW
    Freitag, P
    Guseo, A
    Daumer, M
    Mertin, J
    MULTIPLE SCLEROSIS JOURNAL, 2005, 11 (02) : 166 - 168
  • [46] The TOTEM RRMS (Testosterone Treatment on neuroprotection and Myelin Repair in Relapsing Remitting Multiple Sclerosis) trial: study protocol for a randomized, double-blind, placebo-controlled trial
    Katline Metzger-Peter
    Laurent Daniel Kremer
    Gilles Edan
    Paulo Loureiro De Sousa
    Julien Lamy
    Dominique Bagnard
    Ayikoe-Guy Mensah-Nyagan
    Thibault Tricard
    Guillaume Mathey
    Marc Debouverie
    Eric Berger
    Anne Kerbrat
    Nicolas Meyer
    Jérôme De Seze
    Nicolas Collongues
    Trials, 21
  • [47] The TOTEM RRMS (Testosterone Treatment on neuroprotection and Myelin Repair in Relapsing Remitting Multiple Sclerosis) trial: study protocol for a randomized, double-blind, placebo-controlled trial
    Metzger-Peter, Katline
    Kremer, Laurent Daniel
    Edan, Gilles
    De Sousa, Paulo Loureiro
    Lamy, Julien
    Bagnard, Dominique
    Mensah-Nyagan, Ayikoe-Guy
    Tricard, Thibault
    Mathey, Guillaume
    Debouverie, Marc
    Berger, Eric
    Kerbrat, Anne
    Meyer, Nicolas
    De Seze, Jerome
    Collongues, Nicolas
    TRIALS, 2020, 21 (01)
  • [48] A randomized double-blind trial of comparative efficacy and safety of Avonex and CinnoVex for treatment of relapsing-remitting multiple sclerosis
    Pakdaman, Hossein
    Abbasi, Mehdi
    Gharagozli, Koroush
    Ashrafi, Farzad
    Kasmaei, Hosein Delavar
    Harandi, Ali Amini
    NEUROLOGICAL SCIENCES, 2018, 39 (12) : 2107 - 2113
  • [49] A randomized double-blind trial of comparative efficacy and safety of Avonex and CinnoVex for treatment of relapsing-remitting multiple sclerosis
    Hossein Pakdaman
    Mehdi Abbasi
    Koroush Gharagozli
    Farzad Ashrafi
    Hosein Delavar Kasmaei
    Ali Amini Harandi
    Neurological Sciences, 2018, 39 : 2107 - 2113
  • [50] Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 9-month double-blind active extension of the multicenter, randomized, double-blind, parallel-group placebo-controlled study
    Comi, Giancarlo
    Abramsky, O.
    Arbizu, T.
    Boyko, Alexey
    Gold, Ralf
    Havrdova, Eva
    Komoly, Samuel
    Selmaj, Krzysztof
    Sharrack, Basil
    Filippi, Massimo
    MULTIPLE SCLEROSIS, 2008, 14 : S37 - S38
12345